Opposing functions of classic and novel IL-1 family members in gut health and disease

Loris R. Lopetuso1,2, Saleem Chowdhry1,3 and Theresa T. Pizarro1*

1 Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, USA
2 Internal Medicine, Gastroenterology Division, Catholic University of Rome, Rome, Italy
3 Digestive Health Institute, University Hospitals, Cleveland, OH, USA

*Correspondence: Theresa T. Pizarro, Department of Pathology, Case Western Reserve University School of Medicine, 2103 Cornell Road, WRB 5534, Cleveland, OH 44106, USA
e-mail: theresa.pizarro@case.edu

BACKGROUND AND INTRODUCTION

STRUCTURE AND FUNCTION OF THE INTESTINAL GUT MUCOSA

The gastrointestinal (GI) tract, with its epithelial barrier consisting of a total surface area of approximately 200 m², is man’s most widely exposed organ system to the external environment. The intestinal barrier represents a functional unit responsible for two main tasks crucial for survival of the individual: allowing nutrient absorption, and defending the body from penetration of unwanted, often dangerous, macromolecules. In fact, the gut mucosa is a multi-layered system consisting of an external “anatomical” barrier and an inner “functional” immunological barrier. Commensal gut microbiota, a mucous layer, and the intestinal epithelial monolayer constitute the anatomical barrier. The deeper, inner layer consists of a complex network of immune cells organized in a specialized and compartmentalized system known as gut-associated lymphoid tissue or GALT. GALT represents both isolated and aggregated lymphoid follicles and is one of the largest lymphoid organs, containing up to 70% of the body’s total number of immunocytes, and is involved in responding to pathogenic microorganisms and providing immune tolerance to commensal bacteria. The ability of GALT to interact with luminal antigens rests on specific mucosal immune cells (i.e., dendritic cells and M-cells), primarily localized to Peyer’s patches within the ileum, that are intimately positioned at the mucosal-environmental interface and internalize microorganisms and macromolecules. These specialized immune cells have the ability to present antigen to naïve T-lymphocytes, which subsequently produce cytokines and activate mucosal immune responses, when needed. From the intracellular point of view, inflammasomes are a group of protein complexes that assemble upon recognition of a diverse set of noxious stimuli and are now considered the cornerstone of the intracellular surveillance system. They are able to sense both microbial and damage-associated molecular patterns (DAMPs) and initiate a potent innate, anti-microbial immune response (1). The interaction of these components sustains the maintenance of the delicate equilibrium needed for intestinal homeostasis. Many factors can alter this balance, including alterations in the gut microflora, modifications of the mucus layer, and epithelial damage, leading to increased intestinal permeability and translocation of luminal contents to the underlying mucosa (2). The integrity of these structures is necessary for the maintenance of normal intestinal barrier function. Dysregulation of any of the aforementioned components have been implicated not only in the pathogenesis of inflammatory bowel disease (IBD), but many other GI disorders, including infectious enterocolitis, irritable bowel syndrome, small intestinal bowel overgrowth, and allergic food intolerance (3–5).

In addition to their well-established role(s) in the pathogenesis of gastrointestinal (GI)-related inflammatory disorders, including inflammatory bowel disease (IBD) and inflammation-associated colorectal cancer (CRC), emerging evidence confirms the critical involvement of the interleukin-1 (IL-1) cytokine family and their ligands in the maintenance of normal gut homeostasis. In fact, the paradigm that IBD occurs in two distinct phases is substantiated by the observation that classic IL-1 family members, such as IL-1, the IL-1 receptor antagonist (IL-1Ra), and IL-18, possess dichotomous functions depending on the phase of disease, as well as on their role in initiating vs. sustaining chronic gut inflammation. Another recently characterized IL-1 family member, IL-33, also possesses dual functions in the gut. IL-33 is upregulated in IBD and potently induces Th2 immune responses, while also amplifying Th1-mediated inflammation. Neutralization studies in acute colitis models, however, have yielded controversial results and recent reports suggest a protective role of IL-33 in epithelial regeneration and mucosal wound healing. Finally, although little is currently known regarding the potential contribution of IL-36 family members in GI inflammation/homeostasis, another IL-1 family member, IL-37, is emerging as a potent anti-inflammatory cytokine with the ability to down-regulate colitis. This new body of information has important translational implications for both the prevention and treatment of patients suffering from IBD and inflammation-associated CRC.

Keywords: IL-1 family of cytokines, inflammatory bowel disease, colitis, inflammation-associated colon cancer, intestinal homeostasis, Toll/IL-1 receptor family, mucosal wound healing, intestinal fibrosis

www.frontiersin.org July 2013 | Volume 4 | Article 181 | 1
Table 1 | Role of IL-1 cytokine family members in IBD and in GI-related cancers.

| Common name | IL-1 family name | Ligand-binding chain | Disease association | Potential role in IBD | Potential role in GI-related cancers |
|-------------|------------------|----------------------|---------------------|-----------------------|--------------------------------------|
| IL-1α       | IL-1F1           | IL-1R type I         | CD, UC              | Protective during early phase of inflammation | Induction of tumor growth, metastasis formation, and angiogenesis in gastric, liver, colon, and pancreatic cancer |
| IL-1β       | IL-1F2           | IL-1R type I         | CD, UC              | Protective during early phase of inflammation | Induction of tumor growth, metastasis formation, and angiogenesis in gastric, liver, colon, and pancreatic cancer |
| IL-1Ra      | IL-1F3           | IL-1R type I         | UC                  | Potential dual role | Protective in inflammation-associated colon cancer |
| IL-18       | IL-1F4           | IL-18Ra              | CD                  | Protective during early phase of inflammation | Protective in inflammation-associated colon cancer |
| IL-36Ra     | IL-1F5           | IL-1Rrp2             | Unknown             | Unknown               | Unknown |
| IL-36β      | IL-1F6           | IL-1Rrp2             | Unknown             | Unknown               | Unknown |
| IL-37       | IL-1F7           | IL-18Ra              | Unknown for human IBD, antagonist for DSS colitis | Protective (correlates with breakdown of intestinal barrier) | Expressed in colon cancer cells |
| IL-36β      | IL-1F8           | IL-1Rrp2             | Unknown             | Unknown               | Unknown |
| IL-36γ      | IL-1F9           | IL-1Rrp2             | Unknown             | Unknown               | Unknown |
| IL-33       | IL-1F11          | ST2                  | UC                  | Protective             | Possible support of tumor formation and progression |

As such, aside from the established pro-inflammatory properties of IL-1α, IL-1β, IL-18, and their downstream signaling molecules shared with TLR family members, such as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and myeloid differentiation primary response 88 (MyD88), a growing body of evidence indicates that these mediators are necessary for the maintenance of mucosal homeostasis by effectively handling microbiota, as well as by protecting and restoring the integrity of the epithelial barrier (23–25). While little is known regarding the
potential contributions of other IL-1 family members, such as IL-36, IL-36Ra, IL-37, and IL-38, in chronic intestinal inflammation and gut health, the evolving literature regarding the role of IL-33, the most recently described IL-1 family member is, at present, ambiguous and may reflect yet another example of an innate-type cytokine that possesses multiple functions depending on the immunological status and genetic susceptibility of the host. Although one of the first observations of IL-33-dependent functions in the gut was potent epithelial proliferation and mucus production (26), suggesting the promotion of mucosal repair and healing, dysregulated or uncontrolled IL-33 production may also lead to more pathogenic features characteristic of IBD, including epithelial barrier dysfunction, chronic, relapsing inflammation, and formation of fibrotic lesions (27, 28).

In the present review, we will comprehensively evaluate the role of IL-1 family members and their associated ligands in modulating mucosal homeostasis and chronic inflammation within the GI tract, as well as touch on the potential contribution of these important receptor-ligand pairings to GI tumorigenesis and cancer. Moreover, we speculate about the potential implications of the opposing functions of IL-1 family members for treating chronic intestinal inflammation and inflammation-associated colorectal cancer (CRC), as well as in designing more efficacious strategies for the prevention and treatment of these devastating GI pathologies.

**PATHOGENIC ROLE OF CLASSIC IL-1 FAMILY MEMBERS IN CHRONIC INTESTINAL INFLAMMATION AND INFLAMMATION-ASSOCIATED CRC**

**PATHOGENIC EFFECTS OF IL-1α, IL-1β, AND IL-1RA DURING CHRONIC INTESTINAL INFLAMMATION**

IL-1α and IL-1β (IL-1F1 and F2, respectively) are derived from different genes, but are functionally similar, and both bind to the IL-1R type I (IL-1RI) (Figure 1). This is followed by recruitment of the co-receptor chain, IL-1R accessory protein (IL-1RAcP), and

---

**FIGURE 1 | Receptor-ligand pairing of IL-1 family members.** Productive pairings of ligand, binding receptor, and accessory protein for the IL-1 (upper left), IL-18/IL-37 (upper right), IL-33 (lower left), and IL-36/IL-38 (lower right) systems. The overall bioactivity of IL-1 family agonists is dependent on the prevalent isoform and receptor binding domain/accessory protein present on effector cells. Promiscuous receptor/co-receptor binding of agonists and antagonists imply that IL-1 family members cannot be considered in isolation, but in the context of other IL-1 family members that can influence their overall integrative effects and impact on disease pathogenesis.
a receptor complex is formed. The IL-1R complex can then recruit
the adaptor protein, MyD88, to the TIR domain, after which several
kinases are phosphorylated, NF-κB translocates to the nucleus,
and the transcription of several inflammatory genes takes place
(Figure 2). Although they exhibit similar biological activities, IL-
1α and IL-1β differ in the manner in which they are processed and
secreted. IL-1α is localized in the cytosol or cell membrane and
is believed to regulate the intracellular environment (29), but can
also be secreted into the extracellular compartment and serve as
a soluble mediator (30). In contrast, IL-1β is first cleaved to its
mature active form and then secreted extracellularly. Patients with
infectious or inflammatory conditions exhibit elevated plasma
concentrations of IL-1β but not IL-1α, suggesting a systemic role
for IL-1β (30). With the sole exception of IL-1 receptor antagonist
(IL-1Ra), each member of the IL-1 family is first synthesized as a
precursor molecule without a clear signal peptide for processing
and secretion. IL-1α, similar to the newest member of the IL-1
family, IL-33, has the ability to bind its precursor form to IL-1Rs
and trigger signal transduction. Moreover, both IL-1β and IL-33
are also considered “dual-function” cytokines in that, in addition to
binding to their respective cell surface receptors, their intracellular
precursor forms have the ability to translocate to the nucleus and
can influence subsequent downstream transcription (31, 32). In
general, the nuclear function of IL-1α or IL-33 is transcription of
pro-inflammatory genes. In contrast, the precursor forms of IL-1β
and IL-18 do not bind to their respective receptors, are not active,
requiring cleavage by either intracellular caspase-1 or extracellular
neutrophilic proteases (6).

The biologic effects of IL-1 are regulated by naturally produced
inhibitors, including IL-1Ra (IL-1F3), that binds to the IL-1RI
and is specific for preventing the activity of IL-1α and IL-1β,
without possessing any agonist function (6, 33). In addition, binding
to the IL-1 receptor type II (IL-1RII), expressed mostly on
macrophages, neutrophils, and B cells, does not result in produc-
tive signaling due to the lack of a cytoplasmic domain, for which
 docking of MyD88 cannot take place. IL-1RII binds IL-1β with
a greater affinity than IL-1RI and works as a decoy receptor by
sequestering IL-1β, thereby operating as a functional IL-1 antago-
nist. Because IL-1RaCIP is recruited to the IL-1RII-IL-1β complex,
the decoy receptor also serves to sequester the accessory receptor
from participating in IL-1 signaling through IL-1RI (6). Finally,
an additional tactic that IL-1Rs use to regulate the activity of IL-1
is by proteolytic cleavage of their extracellular domains. Shedding
of IL-1RII results is the soluble form of IL-1RII (sIL-1RII) that
has an increased affinity for IL-1β compared to IL-1α and IL-1Ra
(34–38), thereby contributing to the antagonism of IL-1 by prefer-
e ntially neutralizing IL-1β’s bioactivity. In addition, an alternate
form of IL-1RaCIP also exists that consists of only its extracellular

FIGURE 2 | Common signaling pathway for Toll/IL-1R (TIR) family
members. TLRs possess significant homology to IL1R family members and
share a similar cytoplasmic TIR domain with receptors of IL-1, IL-18, IL-33, and
IL-36. The TIR domain is essential for recruitment of cytoplasmic adapter
proteins, which in turn initiates downstream signaling cascades. PAMPS, pathogen-associated molecular patterns.
domain; this soluble IL-1RαCp has the ability to associate with ligand-bound sIL-1RII, which results in an increased affinity of binding to both IL-1α and β, further establishing sIL-1RII as a potent inhibitor of IL-1 (39). Conversely, similar to its membrane bound form, sIL-1RI retains that ability to bind IL-1α and IL-1Ra with greater affinity than IL-1β, and can therefore be regarded as promoting a pro-inflammatory phenotype by sequestering IL-1Ra and limiting its anti-inflammatory effects on IL-1R-bearing target cells, and by facilitating free IL-1β to bind to cell surface IL-1RI to promote pro-inflammatory immune responses (36, 38, 40, 41). Therefore, from a clinical perspective, the balance between IL-1 agonists, antagonists, and the amount of surface as well as soluble IL-1Rs affect the overall degree and severity of inflammation in several diseases, including IBD.

Gut mucosal inflammation is characterized by infiltration of neutrophils and mononuclear cells, which upon activation, are important sources of cytokines and other inflammatory mediators. IL-1α and IL-1β play key roles in intestinal inflammation, as they are produced early and induce the production of many other cytokines, amplifying their pro-inflammatory action (6). A marked increase in IL-1 production by isolated lamina propria mononuclear cells (LPMCs), most prominently from tissue histiocytes or macrophages, and by intestinal mucosal tissues has been reported in patients with active IBD by several groups (13, 42–44). Furthermore, tissue levels of IL-1 also closely correlate with the degree of observed mucosal inflammation and necrosis (9).

One of the earliest bodies of work dissecting the role of IL-1 in experimental colitis was performed using a rabbit immune complex–mediated model that possesses some features of UC (9, 12, 45, 46). Results from these studies have provided insight into the bi-directional effects of an innate-type cytokine (i.e., IL-1). In this model, both IL-1α and IL-1β are increased in the inflamed intestinal tissues and display pro-inflammatory properties, as neutralization by either endogenous or exogenous IL-1Ra administration resulted in significant amelioration of colitis (12, 45, 46). Despite these findings, administration of recombinant IL-1β had a similar beneficial effect, indicating that IL-1β is necessary for mucosal protection and maintenance of homeostasis in this model (9). In fact, the currently accepted paradigm is that an imbalance of pro- and anti-inflammatory mediators, as exemplified by the IL-1/IL-1Ra system, is a key mechanism in the pathogenesis of IBD (47).

Interleukin-1 receptor antagonist, primarily produced by intestinal epithelial cells (IECs) and LPMCs within the gut mucosa (48), regulates the bioactivity of IL-1 and a marked decrease in the mucosal IL-1Ra/IL-1 ratio was found in both CD and UC patients when compared to control subjects (13). In this study, the IL-1Ra/IL-1 ratio correlated closely with the clinical severity of disease and was specific for IBD since this trend was not observed in patients with self-limiting colitis. Although the precise mechanism(s) as to why this imbalance occurs in IBD is not specifically known, several groups have reported an association between carriage of the IL-1RN allele 2 (IL-1Rn*2) of the IL-1Ra variable number of tandem repeats (VNTR) polymorphism and low production of IL-1Ra, as well as increased severity of disease in UC patients of several ethnic backgrounds (49–51). Finally, as indicated earlier, the expression and presence of cell surface and soluble IL-1Rs can affect the severity and overall disease phenotype that manifests in patients with IBD. In a study that surveyed circulating plasma and colonic tissue levels of IL-1α, IL-1β, IL-1Ra, sIL-1RI, and sIL-1RII from IBD patients and controls, it was found that sIL-1RII served as a systemic biomarker of disease activity in CD patients, while local shedding of the functional antagonist, sIL-1RII, was associated with decreased colonic inflammation in CD, but not in UC, patients (52).

Taken together, the pathogenesis of chronic intestinal inflammation is characterized by a robust elevation of IL-1 family members promoting agonist activity, including IL-1α and IL-1β, whose primary source are LPMCs of myeloid lineage. A recent study, however, also provides evidence that during acute experimental colitis, IL-1α is potently produced by the intestinal epithelium (53). At the same time, production of IEC- and LP macrophage-derived IL-1Ra is not adequate to overcome the overwhelming pro-inflammatory effects of IL-1, resulting in perpetuation of chronic intestinal inflammation. This deficit in IL-1Ra can be due to carriage of a genetic polymorphism that infers low production, particularly in UC patients. Aside from IL-1 ligands, another facet of overall IL-1 biology to consider in a disease setting is the contribution of IL-1Rs. Within the gut mucosa, almost all cell types have the ability to respond to IL-1 ligands and express IL-1R1 and II. The ability of these cells to shed soluble forms of IL-1Rs have indicated that sIL-1RII plasma levels may serve as a biomarker for disease activity and local sIL-1RII is associated with decreased colonic inflammation, specifically in CD patients. To date, however, a comprehensive study as to the precise distribution of IL-1Rs, including their co-receptors, their cellular sources, and potential trigger(s) to induce shedding during chronic intestinal inflammation, has not been performed. The results derived from these studies would provide critical information regarding the precise contribution of different IL-1R-bearing gut mucosal cell types during the course of disease, as well as aid in the design of more effective therapies to restore the IL-1/IL-1Ra imbalance (Figure 3).

**PATHOGENIC EFFECTS OF IL-1α, IL-1β, AND IL-1RA IN GI-RELATED CANCERS**

In addition to their contribution to chronic intestinal inflammation, IL-1 has also been implicated in tumorigenesis and tumor progression in the GI tract. Cancer cells can directly produce IL-1 or can induce cells within the tumor microenvironment to do so (54). IL-1β is upregulated in colon cancer, and patients with IL-1β-producing tumors generally possess a bad prognosis (55–57). The expression patterns of IL-1, in general, vary since it is expressed in either an autocrine or paracrine fashion (58). Co-culture studies on human melanocytic cells showed that IL-1α and IL-1 β exhibit autocrine behavior by stimulating tumor cells themselves to invade and proliferate, or exert paracrine effects on stromal cells in the microenvironment. The exact mechanism(s) by which IL-1 promotes tumor growth remain unclear, although it is believed to act primarily in an indirect fashion. In human colon cancer lines, IL-1 induces expression of metastatic genes, such as matrix metalloproteinases (MMPs), and stimulates nearby cells to produce angiogenic proteins and growth factors (59), including vascular endothelial growth factor (VEGF), IL-8, IL-6, tumor necrosis factor (TNF), and transforming growth factor (TGF)β (30, 60–62).
The effects of the same IL-1 family member can vary, and are often dichotomous, depending on the cell source, phase of disease (early vs. late), and inflammatory state (acute vs. chronic) of the host. IECs and APCs are critically involved in maintaining gut homeostasis, but also in triggering gut inflammation. icIL-1Ra, IL-18, and IL-33 released by IECs, together with sIL-1Ra, IL-37, and low levels of IL-1β produced by APCs, and sIL-1RII shed by macrophages, promote physiological inflammation, and homeostasis. Chronic intestinal inflammation results when this balance is disrupted, often changing the cellular sources and absolute levels of IL-1 family members. Based on this imbalance, therapeutic strategies aimed at modulating levels of IL-1 family members can be designed to reestablish gut health.

Further studies in IL-1 transgenic mice demonstrate the necessity of IL-1 in tumor growth, metastasis, and angiogenesis (62, 63). Sawai et al. (64) evaluated the role of IL-1 in metastatic and non-metastatic human pancreatic cancer cell lines and showed that metastatic lines demonstrate increased IL-1RI expression compared to non-metastatic cell lines, and exposure to IL-1α results in increased α6- and β1-integrin subunit expression, whereas IL-1α exposure to non-metastatic lines has no effect. Additionally, IL-1α induces adhesion and invasion into laminin in human metastatic cell lines, but not in non-metastatic cell lines. This study highlights the importance of IL-1α for invasiveness and angiogenic properties in vitro, and confirms that only those cancer cell lines that show highly metastatic properties express IL-1α mRNA (65). These findings have also been confirmed for colon and gastric cancers. Human colon cancer-derived IL-1α induces angiogenesis by its action upon the microenvironment, and thereby contributes to metastasis (66). Along this same line, a significant correlation between IL-1α expression and metastasis in human gastric carcinomas has also been established (67, 68). Moreover, increased IL-1 production by gastric epithelial cells leads to gastric inflammation and the development of gastric dysplasia and cancer, as demonstrated in IL-1 transgenic mice (69). In fact, the administration of IL-1Ra has been proposed as a therapeutic regimen for different neoplasias (63). Sawai et al. (64) evaluated the role of IL-1 in metastatic and non-metastatic human pancreatic cancer cell lines and showed that metastatic lines demonstrate increased IL-1RI expression compared to non-metastatic cell lines, and exposure to IL-1α results in increased α6- and β1-integrin subunit expression, whereas IL-1α exposure to non-metastatic lines has no effect. Additionally, IL-1α induces adhesion and invasion into laminin in human metastatic cell lines, but not in non-metastatic cell lines. This study highlights the importance of IL-1α for invasiveness and angiogenic properties in vitro, and confirms that only those cancer cell lines that show highly metastatic properties express IL-1α mRNA (65). These findings have also been confirmed for colon and gastric cancers. Human colon cancer-derived IL-1α induces angiogenesis by its action upon the microenvironment, and thereby contributes to metastasis (66). Along this same line, a significant correlation between IL-1α expression and metastasis in human gastric carcinomas has also been established (67, 68). Moreover, increased IL-1 production by gastric epithelial cells leads to gastric inflammation and the development of gastric dysplasia and cancer, as demonstrated in IL-1 transgenic mice (69). In fact, the administration of IL-1Ra has been proposed as a therapeutic regimen for different neoplasias (63).
AOM/DSS-induced tumorigenesis (77). These findings have been confirmed in Apc\textsuperscript{min} / mice, a spontaneous ileal polyposis model. Introduction of Tir\textsuperscript{8} deficiency into the Apc\textsuperscript{min} / mice leads to increased loss of heterozygosity of Apc and colonic microadenoma formation. Importantly, the increased tumorigenesis in Apc\textsuperscript{min}/Tir\textsuperscript{8−/−} mice is dependent on the presence of the commensal flora, underscoring the role of dysregulated commensal bacteria-TLR signaling in colonic tumor initiation (78).

The impact of the relationship between the gut microbiota and IL-1 family members on colitis-driven CRC also involves the inflammasome. Inflammasomes comprise, in essence, a multiprotein platform for the activation of inflammatory caspases, of which caspase-1 appears to play a dominant role (79). They include a sensor protein, an adaptor protein [apoptosis-associated speck-like protein (ASC) containing a caspase activation and recruitment domain (CARD)], and an inflammatory caspase. Sensor proteins belong to two families of proteins: the nucleotide-binding oligomerization domain (NOD)-like receptor (NLR) family and the pyrin and hemopoietic expression, interferon-inducibility, nuclear localization (HIN) domain-containing protein (PYHIN) family. Tight control of caspase-1 activation by inflammasomes, in particular of NOD-like receptor family pyrin domain-containing 3 (NLRP3, also referred to as Nalp3, CIAS1, or Cryopyrin), is critical since the processing and release of IL-1β and IL-18, as well as a subset of leaderless proteins that facilitate tissue repair, are directly regulated by caspase-1 (80). Homotypic interactions between the pyrin domain in the N-terminus of NLRP3 and the bipartite adaptor protein ASC (encoded by PyCARD) bridge the association of caspase-1 to NLRP3 in the inflammasome. Mice lacking the inflammasome adaptor protein ASC and caspase-1 demonstrate increased disease outcome, morbidity, histopathology, and polyp formation in the AOM/DSS model of CRC (81). The increased tumor burden correlates with attenuated levels of IL-1β and IL-18 at the tumor site. In particular, leucine-rich-repeat-containing Nlrp3\textsuperscript{−/−} mice show an increase in acute and recurring colitis and colitis-associated cancer, although the disease outcome is less severe in Nlrp3\textsuperscript{−/−} mice than in PyCARD\textsuperscript{−/−} or Casp1\textsuperscript{−/−} animals. No significant differences have been found in disease progression or outcome in NLRP3-deficient and PyCARD-deficient mice (82). Bone marrow reconstitution experiments show that Nlrp3 gene expression and function in hematopoietic cells, rather than IECs or stromal cells, is responsible for protection against increased tumorigenesis (81). These data suggest that the inflammasome functions as an attenuator of colitis and colitis-driven CRC. Taken together, the imbalance of IL-1 agonists with IL-1 antagonists and their associated receptors/co-receptors within the GI tract may not be limited to promoting inflammatory processes, but may also be important in tumorigenesis and tumor progression (Figure 4). Re-establishing this balance may represent a new therapeutic target in the treatment of GI-related cancers.

**IL-18 IN CHRONIC INTESTINAL INFLAMMATION**

IL-18 (IL-1F4) was initially characterized as a novel IFN\textit{γ}-inducing factor in mice infected with Propionibacterium acnes and subsequently challenged with a sublethal dose of LPS; as such, this factor was originally coined IFN\textit{γ} inducing factor or IGIF (82).

After cloning, IL-18 was shown to induce IFN\textit{γ} in the presence of a mitogen or IL-2, and these effects were shown to be independent of IL-12 (83). IL-18 is widely expressed throughout various organ systems in the body and in cells of both hematopoietic and non-hematopoietic cell lineages (e.g., macrophages, dendritic cells, Kupffer cells, keratinocytes, osteoblasts, adrenal cortex cells, IECs, microglial cells, and synovial fibroblasts) (14, 84–90). Within the gut mucosa, IL-18 is primarily produced by IECs, tissue histiocytes (or macrophages), and dendritic cells (14, 15, 91). IL-18 exerts its biological effects through binding to the IL-18R complex, which is a heterodimer consisting of an α chain (IL-18Ra or IL-1R related protein 1, IL-1Rrp1), that is responsible for extracellular binding of IL-18, and a non-binding, signal-transducing β chain (IL-18Rβ or Accessory Protein Like, AcPL) (Figure 1). Both chains are members of the IL-1R family and are required for functional IL-18 signaling, that similar to IL-1, occurs through MyD88/IRAK, leading to the downstream activation of NF-κB (92–95) (Figure 2). The IL-18R complex is expressed on a variety of cell types, including T- and B-lymphocytes, macrophages, neutrophils, natural killer cells, endothelial cells, and smooth muscle cells (96–99). It can be upregulated on naïve T cells, Th1 cells, and B cells by IL-12 (93, 100). In contrast, T cell receptor ligation in the presence of IL-4 results in downregulation of the IL-18R complex (101). Although initially described as a Th1 polarizing cytokine, IL-18 has been shown to be a pleiotropic cytokine that can mediate both Th1- and Th2-driven immune responses (102, 103).

![FIGURE 4 | Role of IL-1 family members in colon cancer](www.frontiersin.org)

Similar to chronic intestinal inflammation characteristic of IBD, an imbalance between protective and pathogenic IL-1 family members is also an important mechanism leading to intestinal tumorigenesis and the development of GI-related cancers. In fact, IL-1 cytokines play an important role in sustaining tumor growth by stimulating growth factor production and modulating host immune responses against tumor cells. While the roles of classic IL-1 family members, such as IL-1 and IL-18, have been firmly established, only speculation can be made on other, newer IL-1 family members, such as IL-33, IL-36, and IL-37.
An additional family member that affects the overall bioactivity of IL-18 is the IL-18 binding protein (IL-18BP), a naturally occurring, soluble protein that effectively inhibits IL-18 by preventing its interaction with the endogenous receptor (Figure 1) (104). The human IL-18BP gene encodes at least four distinct isoforms (IL-18BPa-d), which are derived by alternative splicing (105). IL-18BP isoforms a and c neutralize the biological activity of IL-18, whereas b and d do not (106). The high affinity of IL-18 to the IL-18BP has a significant impact on its overall bioactivity and clinical relevance during disease states as ligand passing of IL-18 from the IL-18BP to its cell-bound receptor does not occur due to this unusually tight binding (104, 106, 107). Thus, the IL-18/IL-18BP system possesses several biological activities that underscore the potential for IL-18 to serve as a key mediator in the pathogenesis of several chronic inflammatory disorders, including IBD.

Our group and others were the first to report that IL-18 is upregulated in patients with IBD, particularly in CD (14, 15). IL-18 is present in the serum of CD patients, and bioactive IL-18 expression along with IL-18-induced cytokines are increased in mucosal biopsies of patients with IBD compared to controls, in involved vs. non-involved lesions, and in chronic diseases compared to early asymptomatic disease (14, 15, 91). Interestingly, immunohistochemistry (IHC) studies of colonic tissues derived from IBD patients and controls reveal a distinct pattern of IL-18 expression that may uncover potential IL-18-dependent mechanisms involved in maintaining gut health and in the pathogenesis of chronic intestinal inflammation (14) (Figure 3). In these studies, a dramatic shift in IL-18 expression is observed within the gut mucosa of CD patients as inflammation became more severe. In non-involved areas, IL-18 is immunolocalized almost exclusively to the epithelium, similar to that found in uninflamed tissues from the resected healthy margins of colon cancer patients. As disease severity increases, IL-18 expression switches from the epithelium to the lamina propria, specifically in cells morphologically consistent with tissue histiocytes/macrophages, wherein the most severe cases lack epithelial-derived IL-18. This trend appears to be specific for CD as IL-18 expression in UC patients is limited to the epithelium, independent of disease severity (14).

The IL-18 BP is also differentially expressed in intestinal tissues from IBD patients. Intestinal endothelial cells and macrophages are the major source of IL-18BP in the submucosa, and in CD, an increased number of IL-18BP-expressing macrophages and endothelial cells, specifically isoforms a, c, and d, has been detected (105). The presence of IL-18BP in CD lesions suggests neutralization of IL-18 activity, unless patients with active CD preferentially undergo differential splicing to produce more of the inactive isoforms (b and d) than the a and c bioactive isoforms. These patients would then have a reduced ability to regulate IL-18 activity during the course of the disease. In fact, free IL-18 is still observed in specimens from active CD and highlights the complexity of regulating bioactivity of IL-18. The importance of the IL-18BP in regulating IL-18 has also been reported in pediatric IBD patients, particularly in CD (108). IL-18BP does not sequester all free IL-18, which is increased not only in local gut tissues, but also in the serum of children with active CD.

Although the majority of studies characterizing IL-18 and IL-18BP in IBD have been mostly descriptive in nature, they have laid the foundation that underscores the importance of the balance between IL-18 and IL-18BP in gut health and the pathogenesis of chronic intestinal inflammation, particularly in patients with CD. Similar to assessing global IL-1 bioactivity, expression of the IL-18R/ co-receptor system on effector target cells should also be considered when evaluating the overall biological effects of IL-18. To date, a comprehensive study has not been performed to measure IL-18Rs and/or co-receptors in either CD or UC patients. However, polymorphisms in the IL-18 accessory protein (IL-18RACP/IL-18RACP/IL-18RBP), as well as IL-18, have been linked to IBD susceptibility (109–111). In fact, IL-18 expression is reportedly altered by a number of polymorphisms including three single-nucleotide polymorphisms (SNPs) in the IL-18 promoter at positions -137, -607, and -656, relative to the transcriptional start site (112). Transcription analysis of the first two polymorphisms showed that they cause altered transcription factor binding and gene expression (112). Similarly, SNP rs917997 correlates with altered expression of IL-18BP and is strongly associated with IBD and celiac disease (111, 113).

Animal models of IBD have provided a critical tool to mechanistically determine the potential role of IL-18 during the pathogenesis of colitis (120). Initial studies, in fact, support a pathogenic role for IL-18. In mice with either 2,4,6-trinitrobenzene sulfonic acid (TNBS)- or DSS-induced colitis, intestinal IL-18 levels of both macrophage and epithelial cell origin were found to be markedly elevated (114, 115). IL-18 expression, in co-operation with IL-12, leads to the expansion of TH1 CD4+ T cells (116) and production of the prototypic Th1 cytokines, IFNγ, and TNFα (117). Further evidence that IL-18 plays an important role in the chronic phase of intestinal inflammation was demonstrated using a T-cell dependent adoptive transfer model, wherein local administration of an adenovirus expressing anti-sense IL-18 mRNA had the ability to effectively treat colitis in recipient SCID mice (118). In fact, neutralization or targeted gene deletion of IL-18 results in amelioration of both chemically- and immunologically-mediated colitis (117–120), which may occur through a mechanism wherein local TNF production is dampened (114). Moreover, transgenic over-expression of IL-18 is associated with exacerbated colitis, which displays a marked infiltration of mucosal macrophages (121). The cellular re-distribution of IL-18, from IECs to gut mucosal macrophages, may be responsible for the pro-inflammatory role that IL-18 appears to play during chronic inflammatory responses within the gut mucosa. Using the SAMP1/YitFc (SAMP) model of spontaneous CD-like ileitis (122), our group previously reported that the mouse IL-18 gene is located within an interval on chromosome 9 that confers genetic susceptibility to disease in these mice (123). Similar to human CD, SAMP mice display a dramatic shift in the cellular source of IL-18 as disease becomes more severe, from IECs to LPMCs (124). The temporal and spatial expression of IL-18, in regard to the cellular source, as well as the presence or absence of specific IL-18R bearing cells, may explain the observed differential effects of IL-18 during the innate, early phases, vs. the later, chronic stages, of IBD. Together, these data indicate that IL-18 represents a central mediator in the pathogenesis of intestinal inflammation and is able to play very different roles during the inflammatory process depending on the host’s inflammatory state. As such, therapeutic strategies to alter IL-18 bioactivity need...
to be carefully addressed to determine the appropriate dose (low vs. high) and most beneficial time (early vs. late) to neutralize endogenously produced IL-18 during chronic inflammatory diseases, including IBD (Figure 3).

IL-18 IN INFLAMMATION-ASSOCIATED GI-RELATED CANCERS
Aside from its established role in mucosal innate and adaptive immunity within the GI tract, IL-18 has also been identified as a mediator that both promotes and suppresses the process of oncogenesis (Figure 4). Although discussed in detail later in this review, IL-18’s protective effects include the ability to induce cell death and tumor regression through NK cell activation (125). In experimental cancer models, IL-18 expression in tumor cells has been shown to enhance both specific and non-specific antitumor immune responses (126, 127). On the other hand, IL-18 mRNA expression and serum levels correlate with the development and progression of gastric cancers (128), and may be associated with esophageal carcinoma. IL-18 upregulates expression of VEGF (129) and thrombospondin (130), suggesting its effectiveness in promoting angiogenesis. IL-18 also promotes metastasis by inducing cell adhesion molecules (131) and MMPs (132), while facilitating immune evasion by increasing the expression of Fas ligand on tumor cells (133). Similar to IBD, polymorphisms in the IL-18 promoter region are also strongly associated to GI-related cancers. In particular the rs917997 genotype appears to correlate with patient risk of reflux progressing to Barrett’s and esophageal adenocarcinoma (134, 135). IL-18 promoter polymorphisms are also associated with an increased risk for the development of gastric and colorectal cancers (136, 137).

PROTECTIVE ROLE OF CLASSIC IL-1 FAMILY MEMBERS IN MAINTAINING INTESTINAL HOMEOSTASIS AND GUT HEALTH

PROTECTIVE EFFECTS OF IL-1α, IL-1β, AND IL-1RA
As previously mentioned, initial studies using a rabbit model of colitis revealed the potential dual role of IL-1 as a classic proinflammatory cytokine (12, 46, 138) as well as a mediator that has beneficial effects, particularly the IL-1β isoform, promoting gut mucosal protection (45). Interestingly, protection by IL-1β is only achieved with administration of low dose IL-1β, and only when given 24 h, but not 30 min, before the induction of colitis. Such protective effects of low dose IL-1 have also been shown in other disease models, such as arthritis (139) and sepsis (140). Similarly, in a mouse model of DSS-induced colitis, neutralization of IL-1 activity during the acute phase of disease was associated with exacerbated severity of inflammation and delayed recovery from injury (23). No effect was observed during the chronic stage of colitis, suggesting that IL-1 may have opposing effects during the progression of colitis by inferring protection during early, acute inflammation, but exerting more pro-inflammatory functions in later stages during the chronic phase of disease (Figure 3).

An alternative hypothesis to support the dichotomous role of IL-1 in IBD is that IL-1α and IL-1β possess opposing roles during the progression of chronic intestinal inflammation. In support of this concept, a recent study by Bersudsky et al. demonstrates that the precursor form of IL-1α, derived primarily from damaged IECs following DSS-induced colitis, can act as a classic alarmin by initiating and sustaining colitis, while IL-1α KO mice show little disease with increased recovery (53). Conversely, myeloid cell-derived IL-1β in the same colitic model induces the restitution and repair of IECs and improves gut barrier function during the recovery phase of acute inflammation. Furthermore, while specific blockade of IL-1α leads to amelioration of colitis, administration of IL-1Ra or anti-IL-1β antibodies do not effectively treat DSS colitis (53). Taken together, understanding the potential opposing roles of IL-1 agonists, such as IL-1α and IL-1β, during the initiation and progression of chronic intestinal inflammation, will shed further light on precise therapeutic modalities that will lead to more efficacious treatment of patients with IBD (Figure 3).

IL-18-DEPENDENT PROTECTION DURING INTESTINAL INFLAMMATION
Based on more recent studies, results point to the possibility of IL-18 possessing dichotomous roles during the progression of IBD, which may be related to phase of disease, as well as the cellular sources of both ligand and receptors/co-receptors (25). In fact, at the onset, or initiation of intestinal inflammation, IL-18 derived from IECs may exert a protective role, facilitating tissue repair and promoting mechanisms to induce homeostasis. In support of this concept is the observation that IL-18 and IL-18R KO mice are more susceptible to acute DSS colitis than their WT littermates (141). In addition, epithelial-derived IL-18 is critical for the protection from DSS colitis conferred by NLR-mediated signaling, as shown in studies utilizing mice deficient in Nlrp3 (142).

In fact, similar to IL-1, emerging evidence highlights the control of IL-18 activation and the overall regulation of intestinal mucosal immune responses exerted by the inflammasomes (80). As mentioned earlier, tight regulation of caspase-1 activation by inflammasomes is critical since the processing and release of IL-1β and IL-18 are directly regulated by caspase-1 (80). IL-18 is upregulated at the site of inflammation in DSS-exposed WT, but not in Nlrp3−/−, Pycard−/−, and Casp1−/−, mice (142). Nlrp3, Asc and Caspase-1/11 KO mice are also hyper-sensitive to acute DSS colitis, with low colonic IL-18 levels associated with disease susceptibility, while administration of exogenous IL-18 ameliorates colitis severity (142). Nevertheless, Bauer et al. (143) demonstrated that Nlrp3 KO mice are protected from DSS-induced colitis, suggesting that DSS itself may activate the NLRP3 inflammasome. These results support that concept that different inflammasomes may exert differential and redundant effects on the development and progression of inflammation that may be additive or divergent, resulting in a hierarchical combinatorial net effect on intestinal inflammation (144). Thus, activation of a particular inflammasome in hematopoietic cells, such as dendritic cells and macrophages, may result in local release of IL-1β and/or IL-18 that induces inflammatory changes, such as secretion of IFNγ, while IL-18 secretion from IECs, through a different inflammasome, may play a local role in tissue regeneration and wound mucosal healing in response to injury. Such differential and cell-specific contributions of inflammasome signaling remain to be demonstrated experimentally. Moreover, inflammasomes are able to induce pyroptosis in damaged or infected IECs, which may affect tissue regeneration and consequently, the level of microbial influx into the LP and its effects on the severity of colitis (80). These effects may be induced by different inflammasomes and introduce
a complex net effect based on temporal and microanatomical variations. However, mutations in the inflammasome pathway may also affect colitis differently, depending on the composition of the commensal microbiota that is present in the host since the inflammasome is a critical regulator of colonic microbial ecology (145). This observation also underscores the role of the commensal flora in intestinal immune homeostasis and further demonstrates the complexity of the gut mucosal immune system.

**PROTECTIVE ROLE OF IL-18 IN GI TUMORIGENESIS**

In contrast to its established, pathogenic role in tumorigenesis, IL-18 has been shown to represent a key protective cytokine in the development of inflammation-associated CRC using the AOM/DSS-induced model of colitis-associated cancer (146). An association between chronic inflammation and tumor development and progression is well established and as such, it is not surprising that a cytokine that has protective properties against inflammation can also reduce tumorigenesis associated with chronic inflammation. In fact, IL-18 and IL-18R KO mice are known to be highly susceptible to both DSS-induced colitis and colorectal tumorigenesis (147). In addition, MyD88 KO mice, which are defective in both IL-1β and IL-18 production, exhibit increased colonic epithelial proliferation, damage and colorectal tumorigenesis (147). Furthermore, administration of exogenous IL-18 can alleviate the severity of colitis and colitis-induced tumorigenesis in caspase-1/11 and Nlrp3 KO mice (148). In contrast, IL1R KO mice show equal numbers of colorectal tumors in the CRC AOM/DSS model, highlighting the unique and essential role of IL-18 during intestinal tumor progression (148). As such, and taking into consideration the previous discussion regarding IL-18’s pathogenic role in CRC, the contribution of IL-18 in tumorigenesis and the development of intestinal-specific cancer is clearly dichotomous. However, based on the current data, it appears that, similar to the role of IL-1 family members in intestinal inflammation as well as inflammation-associated CRC, very little has been reported at present (Table 1). In vivo studies on macrophages and epithelial cells overexpressing IL-37b, as well as in vivo experiments in transgenic mice overexpressing human IL-37b, show reduced DC activation and decreased production of pro-inflammatory and Th1/Th17 cytokines, including IL-1β, IL-6, IFNγ, and IL-17 following LPS stimulation. In vivo studies suggest that these effects may be mediated through the Smad3 pathway (156). In addition, IL-37b-tg mice exposed to DSS further upregulate IL-37b expression after epithelial injury and display a significant reduction in the severity of colitis compared to WT controls (16). IL-37 is also expressed in the colorectal carcinoma cell line, CCL-247, and in the stroma of colon cancer tumors, wherein IHC revealed intense staining in plasma cells of both normal and diseased colon, suggesting a potential role of IL-37 in antibody production, B-cell activation, and in colon tumorigenesis (151). Therefore, while initial reports indicate that IL-37 may play an anti-inflammatory role in acute colitis (Figure 3), further studies are warranted to elucidate the precise role in both chronic intestinal inflammation as well as inflammation-associated CRC (Figure 4).

**DICHOTOMOUS ROLE OF IL-33, THE NEWEST MEMBER OF THE IL-1 FAMILY, IN INTESTINAL INFLAMMATION AND MUCOSAL WOUND HEALING**

IL-33, also known as IL-1F11, is a protein with dual function that can act both as signaling cytokine as well as an intracellular nuclear factor (157) (Table 1). In the GI tract, IL-33 is primarily expressed in non-hematopoietic cells, including fibroblasts, adipocytes, smooth muscle cells, endothelial cells, and IECs (26, 158, 159), but is also present in cells of hematopoietic origin, particularly in restricted populations of professional antigen presenting cells, such as macrophages and DCs (26). IL-33 exerts its biological effects through binding to its receptor, IL-1 receptor-like 1 (IL1RL1), also known as ST2 (26, 28), and in the presence of IL-33, ST2 pairs with its co-receptor, IL-1RACP, and signals through mitogen-activated protein kinase (MAPK) and NF-κB-dependent pathways (26, 160) (Figure 2). Similar to IL-18Rα, the co-receptor SIGIRR/TIR8 can also dimerize with ST2 and likely acts as a negative regulator of the IL-33/ST2 signaling pathway, ultimately reducing IL-33’s biological effects.
IL-33 IN MAINTAINING GUT HOMEOSTASIS

In regard to its role in the GI tract, emerging evidence suggests that IL-33 plays a critical role in maintaining normal gut homeostasis. IL-33 enhances mucosal defenses against intestinal parasites and bacteria, as described for Toxoplasma gondii (162), Pseudomonas aeruginosa (163), and Leptospira (164) infection, indicating a primary role in mucosal protection. In addition, one of the earliest observations regarding the biological activity of IL-33 was its ability to promote epithelial proliferation and mucus production (26), which are obvious functions involved in epithelial restitution and repair, as well as overall mucosal wound healing and protection. Similar to IL-1α, increasing evidence also indicates that IL-33 can function as a prototypic “alarmin,” passively released upon cellular damage, stress, or necrosis, and able to serve as a danger signal/alarmin to alert the immune system of a local threat, such as trauma or infection (159, 165–167). In this setting, IL-33 has the ability to signal local, innate immune responses in an effort to mount an effective, physiological inflammatory reaction in order to restore normal gut homeostasis.

IL-33 has also been shown to activate mast cells, which are distributed throughout barrier tissues, such as the skin and mucosa, including the intraepithelial space of the intestine. Mast cells are classically considered important late-stage effector cells during Th2-associated immune responses, such as host responses against parasitic helminths in mucosal tissues (168). However, recent studies show that mast cells are able to initiate and orchestrate type 2 immunity against helminth infection through the regulation of tissue-derived cytokines. In fact, mast cell-deficient mouse strains and mice treated with the mast cell stabilizing agent, cromolyn sodium, show dramatically reduced Th2 priming and type 2 strains and mice treated with the mast cell stabilizing agent, cromolyn sodium, show dramatically reduced Th2 priming and type 2 cytokine production and harbor an increased burden of parasites following infection with the GI helminth, Heligmosomoides polygyrus bakeri and Trichurus muris. In addition, early production of the tissue-derived cytokines IL-25, IL-33, and thymic Stromal lymphopoietin (TSLP), is significantly diminished in mast cell-deficient mice. Finally, repair of mast cell deficiency increases production of IL-25, IL-33, and TSLP, restores progenitor cell number and Th2 priming, and reduces intestinal parasite burden. These data reveal the important link between IL-33 and an innate IgE-independent role for mast cells in orchestrating type 2 immune responses. Mast cell degranulation, which is crucial for the activation of dendritic cells and recruitment of neutrophils and T cells to the site of infection (169–171), is also needed for the enhanced expression and production of the tissue-derived IL-25, IL-33, and TSLP, which are required for the optimal orchestration and priming of type 2 immunity (172, 173) and are obvious, apparent events important in intestinal mucosal protection against infection.

IL-33/ST2 AXIS IN IBD

In regard to chronic intestinal inflammation, it is now well established, and confirmed by several groups, that increased IL-33 expression is associated with IBD when compared to healthy controls, particularly in UC patients (17–20). In addition, a potential genetic predisposition to dysregulated IL-33/ST2 function may exist as a recent study describes the novel observation of association between the rs3939286 IL-33 polymorphism and IBD, and between the IL1RL1 rs13015714 and CD, in a well-characterized Italian cohort of adult and early onset IBD patients (155). The distribution of IL-33 expression in the gut mucosa is primarily localized to non-hematopoietic cells, particularly IECs (17, 18, 20) and myofibroblasts (19). In addition, ex vivo studies on isolated intestinal mucosal cell populations and immunolocalization on full-thickness intestinal tissues show that IL-33 is also expressed by a wide variety of cell types (17, 19, 22), such as fibroblasts, smooth muscle cells, endothelial cells (26, 174), and adipocytes (17, 158). In active UC, IL-33 is localized to, and potently expressed by, IECs, as well as infiltrating LPMCs, belonging to the monocyte/macrophage and B-cell lineages (17–19). It has also been originally reported by Kobori et al. (19), and later confirmed (22), that IL-33 is expressed in activated subepithelial myofibroblasts (SEMFs) situated below ulcerative lesions in UC, but not in CD, patients supporting a potential functional role for IL-33 in ulcer/wound healing, which may be different in UC compared to CD (Figure 3).

Similar to IL-33, its receptor, ST2, is also increased in the intestinal mucosa of IBD patients (17, 18). Importantly, the intestinal tissue expression pattern of ST2 is different in healthy mucosa compared to that found in chronically inflamed IBD patients, wherein ST2 is abundantly expressed in macroscopically non-inflamed colon epithelium, while during chronic inflammatory processes characterizing either UC or CD, its expression is lost/decreased and redistributed (28). This epithelial-derived tissue expression for ST2 appears to be IBD-specific since non-specific colitis (e.g., diverticulitis and infectious colitis) do not present with this same expression pattern (17). Taken together, considering the potential role of IL-33 in promoting mucosal protection, as well as its tissue distribution in IBD, it is tempting to speculate that the primary role for IL-33 is, in fact, to induce epithelial restitution and repair and mucosal healing (27). In addition, further analysis has shown that the ST2 variant for which expression is altered in the epithelium of IBD patients is ST2L, IL-33’s signaling transmembrane receptor (18, 28). As such, it is possible that impaired epithelial ST2L expression, specifically in IBD patients, may represent an inherent epithelial defect or a negative feedback response to chronic exposure of elevated IL-33 concentrations. One cannot rule out, however, that IL-33 may have pathogenic, as opposed to protective, effects by indirectly damaging or disrupting epithelial barrier function through, for example, recruitment of neutrophils and eosinophils, as well as consider its effects in mounting potent Th2, Th17, and potentiate Th1 immune responses that can amplify and sustain chronic intestinal inflammation. In fact, the dichotomous role of IL-33 has been best characterized in the intestine, where it can possess both protective and pro-inflammatory functions, depending upon the immunological status of the host and/or the type and phase of the ongoing inflammatory process (21, 28).

ROLE OF IL-33 IN EXPERIMENTAL MODELS OF ACUTE COLITIS

Interestingly, investigation into the role of IL-33 in the development of intestinal inflammation using an acute model of DSS colitis has generated mixed results, and likely reflects the
dichotomous roles of IL-33 in both inducing inflammation as well as promoting epithelial restitution/repair and mucosal healing. In fact, DSS administration to IL-33 deficient mice results in less severe colitis than in WT controls, with decreased granulocyte infiltration (175), while exogenous administration of IL-33 to DSS-treated mice further aggravates colitis and induces the influx of neutrophils (176), suggesting a pathogenic role of IL-33, at least in an acute inflammatory setting. Although it is unclear as to what factor(s) precisely regulate IL-33 in the gut, it has recently been shown that severe colonic inflammation with a marked increase in IL-33-producing macrophages results after DSS administration to mice expressing a truncated form of the receptor for TGFβ, supporting a pathogenic function for IL-33 during acute colitis and indicate a direct effect of TGFβ on macrophages to limit IL-33 expression (177). Imaeda et al. also reported an exacerbation of DSS-induced colitis upon treatment with IL-33, hypothesized to occur by IL-33-dependent induction of pathogenic Th2 cytokines; although in the same mice, IL-33 restores goblet cells that were found to be depleted in IL-33-untreated mice (178). In addition, during the recovery phase of DSS-induced colitis, while weight recovery is markedly delayed in IL-33 deficient mice, no significant difference in colonic inflammation is observed between these mice and WT littermates (175). The authors propose that in this particular model, IL-33 plays an important role in driving acute, innate immune responses, but is dispensable in the maintenance of chronic intestinal inflammation. Alternatively, the possibility exists that the delayed weight recovery observed in IL-33 deficient mice, but not in WT littermates, is due to the lack of IL-33-driven epithelial regeneration and restoration of barrier function leading to a dampened ability for mucosal healing.

In fact, as opposed to their results obtained from IL-33 treatment in acute DSS colitis, Groß et al. showed that IL-33 administration during repeated, chronic cycling of DSS causes a reduction of colitis, suppresses IFNγ, and decreases bacterial translocation (176), supporting a protective role of IL-33 that the authors suggest may occur by switching from Th1- to Th2-driven immune responses. These results are supported by a recent study using the TNBS-induced model of colitis (179). Although the aforementioned study utilized an acute, 4-day protocol, exogenous administration of IL-33 was shown to ameliorate TNBS-induced colitis and induce the production of Th2-type cytokines (179). In addition, the protective effect of IL-33 was diminished after depletion of T-regulatory cells (Tregs). The authors propose that, mechanistically, IL-33 has an indirect effect on the development of Foxp3+ Treg cells, by increasing the expression of epithelial-derived TSLP and retinoic acid, which promotes the activation of CD103+ DCs (180) and leads to the induction of Foxp3+ Treg development (181). The ultimate IL-33-induced expansion of Foxp3+ Treg facilitates the observed decrease in the severity of colitis.

ROLE OF IL-33 IN EXPERIMENTAL CHRONIC INTESTINAL INFLAMMATION

In SAMP mice, IL-33 expression patterns in the gut mucosa and within the systemic circulation of IBD patients were confirmed (17). IL-33 gut mucosal tissue levels in SAMP mice progressively increase over time and demonstrate a positive correlation with ileal inflammation, with epithelial cells exclusively expressing full-length IL-33 (17). Although the precise, mechanistic role of IL-33 has not yet been addressed in the SAMP model, preliminary studies blocking IL-33 signaling by administration of an antibody against ST2 indicate a pathogenic role during the chronic phase of disease development (182, 183). In fact, neutralization of IL-33 interferes with the massive influx of eosinophils into the gut mucosa (183) and potently decreases fibrosis and fibrogenic gene expression (182), characteristic of SAMP mice. Interestingly, although blockade of IL-33 has a significant effect on decreasing the overall severity of ileal inflammation in SAMP mice, the magnitude of this reduction is approximately 30%, which may reflect a need for optimizing treatment dosage or alternatively, represents an opposing effect of interfering with epithelial repair and mucosal healing. Investigation is further warranted to study the role of IL-33 during the early, acute phase of SAMP ileitis, as well as the specific role of epithelial-derived IL-33 and IL-33’s direct effects on the intestinal epithelium.

IL-33 AND ST2 IN INTESTINAL FIBROSIS

Although the role of IL-33 has not yet been fully investigated in the pathogenesis of intestinal fibrosis, several lines of evidence indicate that the IL-33/ST2 axis may represent an important mediator in this process. Within the gut mucosa, SEMFs have been reported as a primary source of IL-33, specifically in UC patients where they are situated below ulcerative mucosal lesions (19, 22). In fact, Sponheim et al. observed that a prominent feature of IBD-associated IL-33 expression is the accumulation of both fibroblasts and myofibroblasts in ulcerations of UC lesions (22). Although, the association and localization of IL-33-producing SEMFs with mucosal ulcerations suggests an important role in wound healing, one cannot rule out its potential role in gut-associated fibrosis, particularly in the setting of cycling of chronic tissue damage and repair, characteristic of IBD. Taken together, there is clear evidence of the IL-33/ST2 axis in maintaining normal gut homeostasis, particularly in promoting mucosal wound healing and repair. When dysregulated, this important ligand-binding pair can also play a critical role in the progression of chronic inflammation and fibrosis, leading to such GI-related disorders as IBD.

EMERGING ROLE OF THE IL-33/ST2 AXIS IN GI-RELATED CANCERS

Finally, based on the established role of IL-1 family members in GI-related cancers, the possibility exists that IL-33 can likewise play an important role in GI-associated tumor formation. In fact, a recent study has reported elevated IL-33 levels in the serum of gastric cancer patients that correlates with several poor prognostic factors, including depth of invasion, distant metastasis, and advanced stage, but not with the classic tumor markers, CEA and CA 19-9 (184). Of note, however, no significant difference in IL-33 expression was found between four gastric cancer cell lines and the normal gastric cell line,GES-1, which may indicate that IL-33 expression can either be modulated by local environmental factors and/or produced by other cells responding to gastric cancer epithelial cells. As such, the initial observation of increased, circulating IL-33 levels in gastric cancer patients may be related to the progression of the cancer. In addition, based on IL-33’s ability to shift host immune responses to a Th2 phenotype, downregulation of tumor-specific immune responses can occur by inhibiting tumor antigen presentation (185, 186). From this point of view, IL-33 may represent one of the effective weapons tumor cells utilize
in order to create an ideal environment to obtain, and maintain, optimal growth conditions, further supporting the role of the IL-33/ST2 axis in tumor formation and the progression of cancer (Figure 4).

**POTENTIAL CONTRIBUTION(S) OF THE IL-36-RELATED CYTOKINES IN GUT HEALTH AND DISEASE**

In the last two decades, human genome sequence analysis has helped to identify new members of the IL-1 family. Three new members IL-36α, β, and γ, previously known as IL-1F6, IL-1F8, and IL-1F9, respectively, have been shown to bind to a heterodimeric receptor, IL-36R, also known as IL-1 receptor-related protein 2 (IL-1Rrp2), in a manner similar to the binding of IL-1α and IL-1β to IL-1RI. Consistent with the promiscuous nature of IL-1 family members, the IL-36 complex then recruits IL-1RαcP, thereby activating downstream NF-κB and MAPK pathways (187, 188). Interestingly, IL-36 family members also includes a receptor antagonist, IL-36Ra, similar to IL-1Ra, suggesting significant homology between these two IL-1 subfamilies (Figure 1).

At present, there are no known reports regarding the association between IL-36 and chronic intestinal inflammation, including IBD, as well as inflammation-associated CRC. Most of the published studies concerning IL-36 and disease pathogenesis come from either the psoriatic or pulmonary literature. In skin, all three IL-36 agonist ligands are highly expressed in psoriatic skin lesions (189–191). Johnston et al. has shown that TNF and IL-17 stimulation of human keratinocytes can induce IL-36, and IL-36 can, in turn, stimulate production of anti-microbial peptides and MMPs in human epidermal cells (192). Muhr et al. confirmed these findings and demonstrated that IL-17 potently induces greater amounts of IL-36 in keratinocytes obtained from psoriatic patients compared to healthy controls (193). Others have described increased expression of TNF and IL-6 in...
IL-36-stimulated keratinocytes, suggesting a mutual regulation of these inflammatory mediators (194). Recent studies have also supported an important role of IL-36γ in various lung pathologies. IL-36γ expression is reported to be increased in mice after allergen challenge, and intratracheal administration of IL-36γ leads to airway hyper-responsiveness, neutrophil accumulation and pro-inflammatory cytokine production (195–197). In addition, IL-36 signaling promotes Th1 polarization of naïve CD4+ T cells (198) and induction of Th17 immune response in lung disease (196, 199). Finally, increased IL-36α expression was reported in eosinophilic esophagitis, indicating a possible role of IL-36 in Th2-type immune responses (200). Taken together, these data imply an important pro-inflammatory role for IL-36 ligands in chronic immune disorders, although it is unclear at present whether IL-36 is prone to promoting Th1, Th2, and/or Th17 immunity and whether, like other IL-1 family members, IL-36 may possess dichotomous functions in the setting of health and disease states. In addition to the three described IL-36 agonists, the IL-36Ra and IL-38, previously known as IL-1F5 and IL-1F10, respectively, also bind to the IL-36R; however, differently from IL-36α, β, and γ, IL-36Ra and IL-38 both serve as antagonists for the biological activities of IL-36 (187, 188, 190, 201). Interestingly, IL-36Ra has been shown to possess an anti-inflammatory effect localized to the brain and mediated through a unique TIR8/SIGIRR-dependent pathway (202).

On the basis of the limited availability of published data and preliminary findings, IL-36 may potentially play an important role in chronic inflammatory disorders, including IBD. Investigation into the role of the IL-36 family of cytokines in chronic intestinal inflammation and inflammation-associated CRC, in fact, is an active area of research that may uncover further pathogenic mechanisms involved in GI-related pathologies and may provide the foundation for IL-36 to serve as a potential therapeutic target in the near future.

CONCLUSION

The present review provides evidence that members of the IL-1 family of cytokines possess dichotomous, often opposing functions in both the maintenance of normal gut homeostasis and in the pathogenesis of chronic intestinal inflammation and inflammation-associated CRC. We hypothesize that their effects vary, depending on the phase of disease (early vs. late), as well as the inflammatory state (acute vs. chronic) of the host. In general, early activation of the intestinal epithelium by pathogenic organisms and/or other noxious environmental antigens elicits the production of epithelial-derived IL-1 family members, including intracellular (ic)IL-1Ra, IL-1α, IL-18, and IL-33. Epithelial disruption often occurs, facilitating translocation of luminal bacterial products and the recruitment of innate immune cells, primarily neutrophils, and macrophages that are also a potent source of secreted (s)IL-1Ra, IL-1β, IL-18, and IL-33. Normally, early expression of these mediators function to dampen acute inflammation and promote epithelial repair and restitution, with the end goal of limiting gut mucosal damage and restoring intestinal homeostasis. Under conditions of either uncontrolled and/or persistent inflammation (e.g., as a result of innate immune dysfunction or host genetic predisposition), infiltration of adaptive immune cells bearing various IL-1R family members occurs during the later phases of inflammation, making available an effector population able to respond to IL-1-like ligands. For example, the presence of naïve CD4+ T cells expressing the IL-1R8 have the ability to respond to IL-18, and in combination with IL-12, represents one of the most potent stimuli for IFNγ production and Th1 polarized effector responses, thereby promoting chronic Th1-mediated inflammation. Similar effects can occur upon IL-33 stimulation of naïve CD4+ T cells, but in this case, a robust Th2 immune response results. Furthermore, several levels of regulation exist within each subfamily of IL-1 family members, often including the presence of several agonist isoforms (both precursor and mature, cleaved forms), receptor antagonists, as well as soluble and cell-bound decoy receptors. In addition, the promiscuity of IL-1 family ligands with both binding receptors as well as recruited accessory proteins, instills yet another level of regulation that should be considered when determining the overall biological effects of a specific IL-1 family member agonist. In fact, IL-1 family members cannot be considered in isolation, but with other IL-1-related proteins that can influence their overall interactive effects. An imbalance in the equilibrium between IL-1 family components, dependent on prevalent isoform and receptor binding domain/accessory protein present on effector cells, maybe responsible for either driving pathogenic events, including chronic intestinal inflammation, fibrosis, and CRC, or for promoting protection by inducing epithelial repair, mucosal wounding healing, and restoration of gut homeostasis (summarized in Figure 5). Based on this new information and the emerging concept that IL-1 family members can possess opposing role in gut health and disease, novel pathogenic hypotheses can be formed that have important translational implications in regard to the prevention and treatment of chronic intestinal inflammation, including CD and UC, and CRC.

ACKNOWLEDGMENTS

The authors acknowledge continued support from the National Institutes of Health: DK056762, DK091222, and AI102269, and a Research Award from the DeGregorio Family Foundation (all to Theresa T. Pizarro).

REFERENCES

1. Strowig T, Henao-Mejia J, Elitsur Y, Flavell R. Inflamm-omes in health and disease. Nature (2012) 481(7381):278–86. doi:10.1038/nature10759
2. Scaldaferrri F, Pizzoferrato M, Gerardi V, Lopetuso L, Gasbarrini A. The gut barrier: new acquisitions and therapeutic approaches. J Clin Gastroenterol (2012) 46(Suppl):S12–7. doi:10.1097/MCG.0b013e3182ea8e49
3. Camilleri M, Madsen K, Spiller R, Van Meerweld BG, Verne GN. Intestinal barrier function in health and gastrointestinal disease. Neurogastroenterol Motil (2012) 24(6):503–12.
4. Fasano A. Leaky gut and autoimmune diseases. Clin Rev Allergy Immunol (2012) 42(1):71–83. doi:10.1007/s12120-011-0291-x
5. Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev (2011) 91(1):151–75. doi:10.1152/physrev.00003.2008
6. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood (2011) 117(14):3720–32. doi:10.1182/blood-2010-07-273417

Frontiers in Immunology | Inflammation

July 2013 | Volume 4 | Article 181 | 14

Lopetuso et al. IL-1 family in the gut
IL-1 family in the gut

7. Pizarro TT, Cominelli F. Cytokine therapy for Crohn's disease: advances in translational research. Ann Rev Med (2007) 58:433–44. doi:10.1146/annurev.med.58.121205.100607
8. Rutgeerts P, Vermeire S, Van Asche G. Biological therapies for inflammatory bowel diseases. Gastroenterology (2009) 136(4):1182–97. doi:10.1053/j.gastro.2009.02.001
9. Cominelli F, Nast CC, Clark BD, Schindler R, Lirena R, Eysee- lein VE, et al. Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest (1990) 86(3):972–80. doi:10.1172/JCI14799
10. Andus T, Daig R, Vogl D, Aschenbrenner E, Lock G, Hollerbach S, et al. Imbalance of the interleukin 1 system in colonic mucosa – association with intestinal inflammation and interleukin 1 receptor antagonist [corrected] genotype 2. Gut (1997) 41(5):561–7. doi:10.1136/gut.41.5.561
11. Nishiyama T, Mizuyama K, Toyonaga A, Sasaki E, Tanikawa T, Ohtani A, et al. Interleukin-33 expression is up-regulated in inflamed mucosa of ulcerative colitis. Clin Exp Immunol (1997) 107(2):353–8. doi:10.1111/j.1365-2249.1997.291.el184.x
12. McNamee EN, Masterson JC, Jedlicka R, McManus M, Grenz A, Collins CB, et al. Interleukin 37 expression protects mice from colitis. Proc Natl Acad Sci U S A (2011) 108(40):16711–16. doi:10.1073/pnas.1119821108
13. Pastorelli L, Gargi R, Hong G, Spina L, Mattidi B, Scarpa M, et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci U S A (2010) 107(17):8017–22. doi:10.1073/pnas.0912678107
14. Bolognese R, Nunez LE, Diaz-Jimenez D, Farfan N, Candida E, Heine C, et al. Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm Bowel Dis (2010) 16(7):1097–107. doi:10.1002/ibd.21175
15. Kobori A, Yagi Y, Imaeda H, Tanaka M, Ohtani A, et al. Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J Gastroentrol (2010) 45(10):999–1007. doi:10.1007/s00335-010-0245-x
16. Seidlin B, Bjerum JT, Coskun M, Waidya B, Vainer B, Nielsen OF. IL-33 is upregulated in colonocytes of ulcerative colitis. Immunol Lett (2010) 128(1):80–5. doi:10.1016/j.imlet.2009.11.001
17. Zama C, Cominelli MA, Vechi M, Pizarro TT, Novel cytokine signaling pathways in inflammatory bowel disease: insight into the dichotomous functions of IL-33 during chronic intestinal inflammation. Therap Adv Gastroenterol (2011) 4(5):311–23. doi:10.1177/1756283X11401770
18. Dinnar D, Bioactive factor in vivo. J Immunol (2007) 178(2):7613(02)00514-9
19. Symons IA, Young PB, Griffin M, Smith MF Jr, Whisendin TD, Slack JL, Sims JE, et al. Binding of IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids. J Immunol (1994) 153(10):4766–74.
20. Burger D, Chicheportiche R, Giri JG, Dayer JM. The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and inhibited by type I interleukin-1 soluble receptor. J Clin Invest (1995) 96(1):38–41. doi:10.1172/JCI8045
21. Smith DE, Hanna R, Della F, Moore H, Chen H, Farese AM, et al. The soluble form of IL-1 receptor accessory protein enhances the ability of soluble IL-1 receptor to inhibit IL-1 action. Immunity (2003) 18(1):87–96. doi:10.1016/S1074-7613(02)00514-9
22. Gir JG, Wells J, Dower SK, McColl CE, Guzman RN, Slack J, et al. Elevated levels of shed type II IL-1 receptor in sepsis. Potential role for type II receptor in regulation of IL-1 responses. J Immunol (1994) 153(12):5802–9.
23. Pizarro TT, Michel MI, Bentz M, Wotraratandharm I, Smith MF Jr, Foley E, et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease expression and localization in intestinal mucosal cells. J Immunol (1999) 163(11):6829–35.
24. Moneteone G, Trappaso F, Parrillo T, Biancone L, Stella A, Iuliano R, et al. Bioactive IL-18 expression is up-regulated in Crohn's disease. J Immunol (1999) 163(1):143–7.
25. Nishiyama T, Mitsuyama K, Casini-Raggi V, Kam L, Chong YJ, Ferrer M, Casini-Raggi V, et al. Interleukin-1 expression protects mice from colitis. Proc Natl Acad Sci U S A (2011) 108(40):16711–16. doi:10.1073/pnas.1119821108
26. Pastorelli L, Gargi R, Hong G, Spina L, Mattidi B, Scarpa M, et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci U S A (2010) 107(17):8017–22. doi:10.1073/pnas.0912678107
27. Pastorelli L, Gargi R, Hong G, Spina L, Mattidi B, Scarpa M, et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci U S A (2010) 107(17):8017–22. doi:10.1073/pnas.0912678107
28. Pastorelli L, De Salvo C, Cominelli MA, Vecchi M, Pizarro TT. Novel cytokine signaling pathways in inflammatory bowel disease: insight into the dichotomous functions of IL-33 during chronic intestinal inflammation. Therap Adv Gastroenterol (2011) 4(5):311–23. doi:10.1177/1756283X11401770
29. Dinnar D, Bioactive factor in vivo. J Immunol (2007) 178(2):7613(02)00514-9
30. Symons IA, Young PB, Griffin M, Smith MF Jr, Whisendin TD, Slack JL, Sims JE, et al. Binding of IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids. J Immunol (1994) 153(10):4766–74.
31. Smith DE, Hanna R, Della F, Moore H, Chen H, Farese AM, et al. The soluble form of IL-1 receptor accessory protein enhances the ability of soluble IL-1 receptor to inhibit IL-1 action. Immunity (2003) 18(1):87–96. doi:10.1016/S1074-7613(02)00514-9
32. Gir JG, Wells J, Dower SK, McColl CE, Guzman RN, Slack J, et al. Elevated levels of shed type II IL-1 receptor in sepsis. Potential role for type II receptor in regulation of IL-1 responses. J Immunol (1994) 153(12):5802–9.
JM, et al. Effects of recombinant soluble type I interleukin-1 receptor on human inflammatory responses to endotoxin. *Blood* (1996) 88(7):2465–72.

42. Mahida YR, Wu K, Jewell DP. Enhanced production of interleukin-1 beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease. *Gut* (1989) 30(6):835–8. doi:10.1136/gut.30.6.835

43. Youngman KR, Simon PL, West GA, Cominelli F, Rachmilewitz D. Role of interleukin-1 in inflammatory bowel disease – enhanced production during active disease. *Gut* (1990) 31(6):686–9. doi:10.1136/gut.31.6.686

44. Cominelli F, Nast CC, Llerena R, Dinarolo CA, Zipser RD. Interleukin-1 suppresses inflammation in rabbit colitis. Mediation by endogenous prostaglandins. *J Clin Invest* (1990) 85(2):582–6. doi:10.1172/JCI114476

45. Cominelli F, Nast CC, Duchini A, Lee M. Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis. *Gastroenterology* (1992) 103(1):65–71.

46. Cominelli F. Cytokine-based therapies for Crohn's disease – new paradigms. *N Engl J Med* (2004) 351(20):2045–8. doi:10.1056/NEJMtp0404253

47. Daig R, Rogler G, Aschenbrenner E, Vogl D, Falk W, Gros V, et al. Human intestinal epithelial cells secrete interleukin-1 receptor antagonist and interleukin-8 but not interleukin-1 or interleukin-6. *Gut* (2000) 46(5):350–8. doi:10.1136/gut.46.3.350

48. Mansfield JC, Holden H, Tarlow JK, Di Giovin F, McDowell TL, Wilson AG, et al. Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. *Gastroenterology* (1994) 106(2):637–42.

49. Tomaras NG, Minami-Raggi V, Yang H, Di Giovin F, Vecchi M, Kam L, et al. Functional and ethnic association of allele 2 of the interleukin-1 receptor antagonist gene in ulcerative colitis. *Gastroenterology* (1999) 117(4):806–13. doi:10.1016/S0016-5085(99)70338-0

50. Carter MJ, di Giovin F, Jones S, Mee J, Camp NJ, Lobo AI, et al. Association of the interleukin-1 receptor antagonist gene with ulcerative colitis in Northern European Caucasians. *Gut* (2001) 48(4):461–7. doi:10.1136/gut.48.4.461

51. Ludwiczek O, Vannier E, Borggraefe I, Kaser A, Siegmund B, Dinarolo CA, et al. Immalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease. *Clin Exp Immunol* (2004) 136(2):325–9. doi:10.1111/j.1365-2249.2004.02599.x

52. Bersudsky M, Luski L, Fishman D, White RM, Ziv-Sokolovskaya N, Dotan S, et al. Non-redundant properties of IL-1α and IL-1β during acute colon inflammation in mice. *Gut* (2013). doi:10.1136/gutjnl-2012-303239. [Epub ahead of print].

53. Portier M, Zhang XG, Ursula E, Lees D, Jourdan M, Bataille R, et al. Cytokine gene expression and protein and gene expression of intestinal interleukin 1 activity. *Gastroenterology* (1993) 104(3):749–58.

54. Ligumsky M, Simon PL, Karmeli F, Rachmilewitz D. Role of interleukin-1 in inflammatory bowel disease – enhanced production during active disease. *Gut* (1990) 31(6):686–9. doi:10.1136/gut.31.6.686

55. Akagi Y, Liu W, Xie K, Zebrowski B, Shaheen RM, Elin LM. Regulation of vascular endothelial growth factor expression in human colon cancer by interleukin-1beta. *Br J Cancer* (1999) 80(10):1506–11. doi:10.1038/sj.bjc.6990553

56. Vonovon E, Shahivali SF, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. *Proc Natl Acad Sci U S A* (2003) 100(5):2645–50. doi:10.1073/pnas.0437931100

57. Lewis AM, Varghese S, Xu X, Alexander HR. Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutical agent in cancer treatment. *J Transl Med* (2006) 4:44. doi:10.1186/1479-5867-4-48

58. Sawai H, Funahashi H, Yamamoto M, Okada Y, Hayakawa T, Tanaka M, et al. Interleukin-1 alpha enhances integrin alpha(1)/beta(1) expression and metastatic capability of human pancreatic cancer. *Oncology* (2003) 65(2):167–73. doi:10.1159/000072343

59. Sawai H, Okada Y, Funahashi H, Matsuo Y, Takahashi H, Takeyama H, et al. Interleukin-1 alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha(1)beta(1)-integrin and urokinase plasminogen activator receptor expression. *BMC Cell Biol* (2006) 7:8. doi:10.1186/1471-2121-7-8

60. Matsuo Y, Sawai H, Ma J, Xu D, Ochi N, Yasuda A, et al. IL-1alpha secreted by colon cancer cells enhances angiogenesis: the relationship between IL-1alpha release and tumor cells’ potential for liver metastasis. *J Surg Oncol* (2009) 99(6):361–7. doi:10.1002/jso.21245

61. Tomatsu S, Ichikura T, Mochizuki H. Significant correlation between expression of interleukin-1alpha and liver metastasis in gastric carcinoma. *Cancer* (2001) 91(7):1227–6. doi:10.1002/1097-0248(20010401)91:7–8227:CID- CNCR1128-10.30.2.C2-Z2-2

62. Sakamoto K, Hikita Y, Nakagawa H, Hayakawa Y, Yanai A, Akamula M, et al. Inhibitor of kappab kinase beta regulates gastric carcinoma genesis via interleukin-1alpha expression. *Gastroenterology* (2010) 139(1):226–38. e6. doi:10.1053/j.gastro.2010.03.047

63. Tsu S, Bhagat C, Cui G, Takashii S, Kurt-Jones EA, Rickman B, et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. *Cancer Cell* (2008) 14(5):408–19. doi:10.1016/j.ccc.2008.11.004

64. Garlanda C, Riva F, Veliz T, Polentarutti N, Pasqualini F, Radaelli E, et al. Increased susceptibility to colitis-associated cancer of mice lacking TIRB, an inhibitory member of the interleukin-1 receptor family. *Cancer Res* (2007) 67(13):6017–21. doi:10.1158/0008-5472.CAN-07-0560

65. Mantovani A, Locati M, Polentarutti N, Vecchi A, Garlanda C. Extracellular and intracellular decoys in the tuning of inflammatory cytokines and Toll-like receptors: the new enemy of TIRB/SigIRR. *J Leukoc Biol* (2004) 75(5):738–42. doi:10.1189/jlb.0104347

66. Wald D, Qin J, Zhao Z, Qian Y, Naramura M, Tian L, et al. SIGIRR, a negative regulator of Toll-like receptor-interleukin-1 receptor signaling. *Nat Immunol* (2003) 4(9):928–7. doi:10.1038/nri968

67. Thomassen E, Renshaw BR, Sims JE. Identification and characterization of SIGIRR, a molecule representing a novel sub-type of the IL-1R superfamily. *Cytokine* (1999) 11(6):389–99. doi:10.1006/cyto.1998.0452

68. Polentarutti N, Röd GR, Muzio M, Bossio D, Cammasio M, Riva F, et al.
al. Unique pattern of expression and inhibition of IL-1 signaling by the IL-1 receptor family member TIR8/SIGIRR. Eur Cytokine Netw (2003) 14(4):211–8.

75. Garlanda C, Riva F, Polentarutti N, Buracchi C, Sironi M, De Bortoli M, et al. Intestinal inflammation in mice deficient in TIR8, an inhibitory member of the IL-1 receptor family. Proc Natl Acad Sci U S A (2004) 101(10):3522–6. doi:10.1073/pnas.0308680101.

76. Qin J, Qian Y, Xiao J, Grace C, Li X. SIGIRR inhibits interleukin-1 receptor and Toll-like receptor 4-mediated signaling through different mechanisms. J Biol Chem (2005) 280(26):25233–41. doi:10.1074/jbc.M50336200.

77. Xiao H, Guleen MF, Qin J, Yao J, Bulek K, Kish D, et al. The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis. Immunity (2007) 26(4):461–75. doi:10.1016/j.immuni.2007.02.012.

78. Xiao H, Yin W, Khan MA, Guleen MF, Zhou H, Shan HP, et al. Loss of single immunoglobulinulin interleukin-1 receptor-related molecule leads to enhanced colonic polyposis in Apc(min) mice. Gastroenterology (2010) 139(2):574–85. doi:10.1053/j.gastro.2010.04.043.

79. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-1 beta. Mol Cell (2002) 10(2):417–26. doi:10.1016/S1097-2765(02)00599-3.

80. Elinav E, Hena-Mejia J, Flavell RA. Integrative inflammasome activity in the regulation of intestinal mucosal immune responses. Mucosal Immunol (2013) 6(1):4–13. doi:10.1038/mi.2012.115.

81. Allen IC, TeKippe EM, Woodford RM, Uronis JM, Holl EK, Rogers AR, et al. The NLRPs inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med (2010) 207(5):1045–56. doi:10.1084/jem.20100050.

82. Okamura H, Nagata K, Komatsu T, Tanimoto T, Nakata Y, Tanabe F, et al. A novel costimulatory factor for gamma interferon induction found in the livers of mice causes endotoxic shock. Infect Immun (1995) 63(10):3966–72.

83. Kohno K, Katoaka J, Ohtsuki T, Suenoto Y, Okamoto I, Usui M, et al. IFN-gamma-inducing factor (IGIF) is a costimulatoritory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. J Immunol (1997) 158(4):1541–50.

84. Udagawa N, Horwood NJ, Elliott J, Mackay A, Owens J, Okamura H, et al. Interleukin-18 (interferon-gamma-inducing factor) messenger RNA and functional protein by induction of IL-12 and IL-18 production from Kupffer cells. J Exp Med (1997) 185(6):1005–12. doi:10.1084/jem.185.6.1005.

85. Stoll S, Muller G, Karimoto M, Sologa J, Tanimoto T, Yamauchi H, et al. Production of IL-18 (IFN-gamma-inducing factor) messenger RNA and functional protein by macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation. J Exp Med (1997) 185(6):1005–12. doi:10.1084/jem.185.6.1005.

86. Conti B, Jahng JW, Tinti C, Son JH, Job TH. Induction of interferon-gamma inducing factor in the adrenal cortex. J Biol Chem (1997) 272(4):2035–7. doi:10.1074/jbc.272.4.2035.

87. Matsui K, Yoshimoto T, Tsutui H, Hyodo Y, Hayashi N, Hiroishi K, et al. Propionibacterium acnes treatment diminishes CD4+ NK1.1+ T cells but induces type 1 T cells in the liver by induction of IL-12 and IL-18 production from Kupffer cells. J Immunol (1997) 159(1):298–302.

88. Stoll S, Joneuleit H, Schmitt E, Muller G, Yamauchi H, Karimoto M, et al. Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development. Eur J Immunol (1998) 28(10):3231–9. doi:10.1002/1521-4141(199810)28:10<3231::AID-IMMU3231>3.0.CO;2-H.

89. Prinz M, Hanisch UK. Murine microglial cells produce and respond to interleukin-18. J Neurochem (1999) 72(5):2215–8. doi:10.1046/j.1471-4159.1999.0722215.x.

90. Gracie JA, Robertson SE, Mclnnes IB. Interleukin-18. J Leukoc Biol (2003) 73(2):213–24. doi:10.1189/jlb.0602313.

91. Kanai T, Watanabe M, Okazawa A, Nakamura K, Okamoto M, Nagahama M, et al. Interleukin 18 is a potent proliferative factor for intesti- nal mucosal lymphocytes in Crohn’s disease. Gastroenterology (2000) 119(6):1514–23. doi:10.1053/gast.2000.20260.

92. Terioke G, Ushio S, Okura T, Kobayashi S, Tanai M, Kunikata T, et al. Purification and characterization of the human interleukin-18 receptor. J Biol Chem (1997) 272(41):25373–42. doi:10.1074/jbc.272.41.25373.

93. Hoshino K, Tsutsui H, Kawai T, Takeda K, Nakashima K, Takeda Y, et al. Cutting edge: generation of IL-18 receptor-deficient mice: evidence for IL-1 receptor-related protein as an essential IL-18 binding receptor. J Immunol (1999) 162(9):5041–4.

94. Pernet P, Garka KE, Bonnert TP, Dover SK, Sims JE. IL-1Rp7 is a novel receptor-like molecule similar to the type I interleukin-1 receptor and its homologues TNF/ST2 and IL-1R ApC. J Biol Chem (1999) 274(8):5967–70.

95. Born TL, Thomassen E, Bird TA, Sims JE. Cloning of a novel receptor subunit, ApCL, required for interleukin-18 signaling. J Biol Chem (1998) 273(45):29445–50. doi:10.1074/jbc.273.45.29445.

96. Leung BP, Culshaw S, Gracie JA, Hunter D, Canetti CA, Campbell C, et al. A role for IL-18 in neutrophil activation. J Immunol (2001) 167(5):2879–86.

97. Hyodo Y, Matsui K, Hayashi N, Tsutui H, Kashwamura S, Yamauchi H, et al. IL-18 up-regulates perforin-mediated NK activity without increasing perforin messenger RNA expression by binding to constitutively expressed IL-18 receptor. J Immunol (1999) 162(3):1662–8.

98. Gerdes N, Sukhova GK, Libby P, Variola virus IL-18 binding protein interacts with three human IL-18 residues that are part of the IL-18 receptor. J Immunol (2002) 168(7):3608–16.

99. Kim SH, Eisenstein M, Reznikov L, Fantuzzi G, Reznikov LL, Dinarello CA, Rubinstein M. Interleukin-18 binding protein: a novel modula- tor of the Th1 cytokine response. Immunity (1999) 10(1):127–36. doi:10.1016/S1074-7613(00)00813-8.

100. Corbaz A, Ten Have T, Herren S, Graber P, Schwarzbard B, Belzer I, et al. IL-18-binding protein expression by endothelial cells and macrophages is up-regulated during active Crohn’s disease. J Immunol (2002) 168(7):3608–16.

101. Yoshimoto T, Takeda K, Tanaka T, Ohkusu K, Kashwamura S, Oka- mura H, et al. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J Immunol (1998) 161(7):3400–7.

102. Lopetuso et al. IL-1 family in the gut

www.frontiersin.org

July 2013 | Volume 4 | Article 181 | 17
110. Leach ST, Messina I, Lemberg DA, Novick D, Rubenstein M, Day AS. Local and systemic interleukin-18 and interleukin-18-binding protein in children with inflammatory bowel disease. Inflamm Bowel Dis (2008) 14(1):68–74. doi:10.1002/ibd.20272

112. Giedraitis V, He B, Huang Y. Tamura K, Fukuda Y, Sashio H. IL-1 family in the gut

113. Hunt KA, Zhernakova A, T en Hove T, Corbaz A, Amitai H. Molecular analysis of the human interleukin-18 gene promoter polymorphisms and inflammatory bowel disease in a Japanese population. Inflamm Bowel Dis (2005) 11(12):1038–43. doi:10.1097/01.MIB.0000182868.67025.b9

114. Kanai T, Watanabe M, Okazawa T, Sato T, Yamanaka M, Okamoto S, et al. Macrophage-derived IL-18-mediated intestinal inflammation in the murine model of Crohn's disease. Gastroenterology (2001) 121(4):875–88. doi:10.1016/s0016-5085(00)00407-0

115. Zernakova A, Festen EM, Franke L, Trynka G, van Diemen CC, Monosur AI, et al. Genetic analysis of innate immunity in Crohn's disease and ulcerative colitis identifies two susceptibility loci harboring CARD9 and IL1R8. Am J Hum Genet (2008) 82(5):1202–10. doi:10.1016/j.ajhg.2008.03.016

116. Brünenberg M, et al. Newly identified genetic risk variants for celiac disease related to the development of colitis with markedly infiltrated macrophages in interleukin-18 transgenic mice. J Gastroenterol Hepatol (2003) 18(6):960–9. doi:10.1046/j.1440-1746.2003.03097.x

117. Pizarro TT, Pastorelli L, Bamias G, Garig RR, Reuter BK, Mercado JP, et al. SAMP1/YitFc mice: a spontaneous model of Crohn's disease-like ileitis. Inflamm Bowel Dis (2011) 17(12):2566–84. doi:10.1002/ibd.21638

118. Carrascal MT, Mendoza L, Valcarcel M, Salado C, Egilegor E, Telleria N, et al. IL-18 binding protein reduces b16 melanoma hepatic metastasis by neutralizing adhesiveness and growth factors of sinusoidal endothelium. Cancer Res (2003) 63(2):491–7.

119. Ten Have T, Corbaz A, Amitai H, Aloni S, Belzer I, Graber P, et al. Blockade of endogenous IL-18 ameliorates TNBS-induced colitis by decreasing local TNF-alpha production in mice. Gastroenterology (2001) 121(6):1372–9. doi:10.1053/gast.2001.29579

120. Mahomed N, Colpaert C, Liu Z, Buellens DA, van Assche G, et al. Interleukin-18 in Crohn's disease: evidence from in vitro analysis of human gut inflammatory cells and from experimental colitis models. Clin Exp Immunol (2004) 135(2):310–7. doi:10.1111/j.1365-2249.2004.02362.x

121. Pizarro TT, Arsenneau KO, Cominelli F. Lessons from genetically engineered animal models XI. Novel mouse models to study pathogenic mechanisms of Crohn's disease. Am J Physiol Gastrointest Liver Physiol (2000) 278(5):G665–9.

122. Cho D, Kim TG, Lee W, Huang YI, Cho HI, Han H, et al. Interleukin-18 and the costimulatory molecule B7-1 have a synergistic anti-tumor effect on murine melanoma; implication of combined immunotherapy for poorly immunogenic malignancy. J Invest Derma tol (2000) 114(5):928–34. doi:10.1038/sj.jid.5500685

123. Wang Y, Zhong S, Lu Y, Peng JP, Guo QS, Wang J. Study on interleukin-18 gene transfer into human breast cancer cells to prevent tumorigenesis. J Zhejiang Univ Sci (2004) 5(4):472–6. doi:10.1631/jzus.2004.0472

124. Xia D, Li F, Xiang J. Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity. Cancer Biother Radio pharm (2004) 19(3):322–30. doi:10.1089/1084978041424990

125. Wei YS, Lan Y, Liu YG, Tang XX, Yang Y, Xiong Y, et al. Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric cancer. World J Gastroenterol (2007) 13(11):1747–51.

126. Kim KE, Song H, Kim YS, Yoon D, Kim CW, Bang SI, et al. Interleukin-18 is a critical factor for vascular endothelial growth factor-enhanced migration in human gastric cancer cell lines. Oncogene (2007) 26(10):1468–76. doi:10.1038/sj.onc.1210926

127. Zhang B, Wu KF, Cao ZY, Ruo Q, Ma XT, Zheng GG, et al. IL-18 increases invasiveness of HL-60 myeloid leukemia cells: up-regulation of matrix metalloproteinases-9 (MMP-9) expression. Leuk Res (2004) 28(1):91–5.

128. Cho D, Song H, Kim YM, Hosh D, Hur DY, Park H, et al. Endogenous interleukin-18 modulates immune escape of murine melanoma cells by regulating the expression of Fas ligand and reactive oxygen intermediates. Cancer Res (2000) 60(10):2703–9.

129. Babar M, Ryan AW, Anderson LA, Segurado R, Turner G, Murray LJ, et al. Genes of the interleukin-18 pathway are associated with susceptibility to Barrett's esophagus and esophageal adenocarcinoma. Am J Gastroenterol (2012) 107(9):1331–41. doi:10.1038/ajg.2012.134

130. Kim KE, Song H, Kim YS, Yoon D, Kim CW, Bang SI, et al. Interleukin-18 is a critical factor for vascular endothelial growth factor-enhanced migration in human gastric cancer cell lines. Oncogene (2007) 26(10):1468–76. doi:10.1038/sj.onc.1210926

131. Carrascal MT, Mendoza L, Valcarcel M, Salado C, Egilegor E, Telleria N, et al. IL-18 binding protein reduces b16 melanoma hepatic metastasis by neutralizing adhesiveness and growth factors of sinusoidal endothelium. Cancer Res (2003) 63(2):491–7.

[Frontiers in Immunology | Inflammation | Volume 4 | Article 181 | July 2013]
low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal gram-negative infection. Proc Natl Acad Sci U S A (1988) 85(5):1620–3. doi:10.1073/pnas.85.5.1620

141. Takagi H, Kanai T, Okawara A, Kishi Y, Sato T, Takashii H, et al. Contrasting action of IL-12 and IL-18 in the development of dextran sodium sulphate colitis in mice. Scand J Gastroenterol (2003) 38(8):837–44. doi:10.1080/0036552030004477

142. Zaki MH, Vogel P, Kasiri MB, Lamkanfi M, Kanneganti TD. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity (2010) 32(3):379–91. doi: 10.1016/j.immuni.2010.03.003

143. Bauer C, Duewell P, Mayer A, Kishi Y, Sato T, Takaishi H, et al. IL-1-like protein that binds IL-18 receptor/IL-1Rrp. Cytokine (2001) 13(1):1–7. doi:10.1006/cyto.2000.0799

144. Pan G, Riser P, Mao W, Baldwin DT, Zhong AW, Filavorev E, et al. IL-1H, an interleukin-1-related protein that binds IL-18 receptor/IL-1Rrp. Cytokine (2002) 18(2):61–71. doi:10.1006/cyto.2002.0873

145. Bufler P, Azam T, Gamboni-Robertson F, Reznikov L, Kumar S, Dinarello CA, et al. A complex of the IL-1 homologue IL-17B and IL-18-binding protein reduces IL-18 activity. Proc Natl Acad Sci U S A (2002) 99(21):13723–8. doi:10.1073/pnas.212519099

146. Nold NF, Nold CA, Lo C, Li S, Rudloff I, Zepp JA, et al. Interleukin 37 employs the IL-1 family inhibitory receptor SIGIRR and the alpha chain of the IL-1 receptor to suppress innate immunity [abstract]. Cytokine (2013).

147. Sharma S, Kulk N, Nold MF, Graf R, Kim SH, Reinhardt D, et al. The IL-1 family member 7b translocates to the nucleus and down-regulates proinflammatory cytokines. J Immunol (2008) 180(8):5477–82.

148. Boraschi D, Lucchese D, Hainzl S, Leitner M, Maier E, Mang gelberger D, et al. IL-37: a new anti-inflammatory cytokine of the IL-1 family. Eur Cytokine Netw (2011) 22(3):127–47. doi:10.1684/ecn.2011.0288

149. Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA. IL-37 is a fundamental inhibitor of innate immunity. Nat Med (2010) 16(3):491–20. doi:10.1038/nm.20246

150. Kumar S, McDonnell PC, Lehr R, Tierney L, Tzimas MN, Griswold DE, et al. Identification and initial characterization of four novel members of the interleukin-1 family. J Biol Chem (2000) 275(14):10308–14. doi:10.1074/jbc.275.14.10308

151. Wood IS, Wang B, Trayhurn P. IL-33, a recently identified interleukin-1 gene family member, is expressed in human adipocytes. Biochem Biophys Res Commun (2009) 384(1):105–9. doi:10.1016/j.bbrc.2009.04.081

152. Mouscin K, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel “alarmin”? PLoS ONE (2008) 3(10):e3331. doi:10.1371/journal.pone.0003331

153. Nakae S, Suto H, Berry GJ, Henriquex FL, et al. IL-33 receptor (T1/ST2) signalling is necessary to prevent the development of encephalitis in mice infected with Toxoplasma gondii. Eur J Immunol (2010) 40(2):426–36. doi:10.1002/eji.200939705

154. Huang X, Du W, Barrett RP, Hazlett LD. ST2 is essential for Th2 responsiveness and resistance to Pseudomonas aeruginosa keratitis. Invest Ophthalmol Vis Sci (2007) 48(10):4626–33. doi:10.1167/iovs.07-0316

155. Wagenaar JP, Gasem MH, Geris MG, Leelang M, Hartskoerl RA, van der Poll T, et al. Soluble ST2 levels are associated with bleeding in patients with severe Leptospirosis. PLoS Negl Trop Dis (2009) 3(6):e453. doi:10.1371/journal.pntd.0000453

156. Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci U S A (2009) 106(20):8201–6. doi:10.1073/pnas.0812690106

157. Luthi AU, Cullen SP, McNeela EA, Duriez PJ, Afnona IS, Sheridan C, et al. Suppression of interleukin-1β bioactivity through proteolysis by apop totic caspases. Immunity (2009) 31(3):84–98. doi:10.1016/j.immuni.2009.05.007

158. Takagi H, Kanai T, Okawara A, Kishi Y, Sato T, Takaishi H, et al. IL-12 and IL-18 in the development of dextran sodium sulphate colitis in mice. Scand J Gastroenterol (2003) 38(8):837–44. doi:10.1080/0036552030004477

159. Lopetuso et al. IL-1 family in the gut
attenuates development and perpetuation of chronic intestinal inflammation. *Inflamm Bowel Dis* (2012) 18(10):1900–9. doi:10.1002/ibd.22990

177. Rani R, Smulian AG, Greaves DR, Hogan SP, Herbert DR. TGF-beta limits IL-33 production and promotes the resolution of colitis through regulation of macrophage function. *Eur J Immunol* (2011) 41(7):2009–18. doi:10.1002/eji.201041135

178. Imaeda H, Andoh A, Aomatsu T, Uchiyama K, Bamba S, Tsujikawa T, et al. Interleukin-33 suppresses Notch ligand expression and prevents goblet cell depletion in dextran sulfate sodium-induced colitis. *Int J Mol Med* (2011) 28(4):573–8. doi:10.3892/ijmm.2011.718

179. Duan L, Chen J, Zhang H, Yang H, Zhu P, Xiong A, et al. IL-33 ameliorates experimental colitis through promoting Th2/Foxp3+(+)-regulating Foxp3 expression and prevents goblet cell depletion in dextran sulfate sodium-induced colitis. *Int J Mol Med* (2011) 28(4):573–8. doi:10.3892/ijmm.2011.718

180. Imaeda H, Andoh A, Aomatsu T, Uchiyama K, Bamba S, Tsujikawa T, et al. Interleukin-33 suppresses Notch ligand expression and prevents goblet cell depletion in dextran sulfate sodium-induced colitis. *Int J Mol Med* (2011) 28(4):573–8. doi:10.3892/ijmm.2011.718

181. De Vita F, Odrirura M, Galizia G, Romano C, Infusino S, Autiero A, et al. Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies. *Cancer* (1999) 86(10):1936–43. doi:10.1002/(SICI)1097-0142(19991115)86:10<1936::AID-CNCR9>3.0.CO;2-0

182. Sharma A, Rajappa M, Saxena A, Sharma M. Cytokine profile in Indian women with cervical intraepithelial neoplasia and cancer cervix. *Int J Gynecol Cancer* (2010) 20(1):133–9. doi:10.1109/ijgmc.2010.542114

183. Dinarello CA, Arend WP, Sims JE, Dinarello CA, Arend WP, Sims JE. Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to acti- vate the pathway leading to NF-kappaB and MAPKs. *J Biol Chem* (2004) 279(14):13677–88. doi:10.1074/jbc.M401172000

184. Debets R, Timans JC, Horney B, Zarouki S, Sana TR, Lo S, et al. Two novel IL-1 family members, II-1 delta and II-1 epsilon, function as an antagonist and agonist of NF-kappaB activation through the orphan IL-1 receptor-related protein 2. *J Immunol* (2001) 167(3):1440–6.

185. Blumberg H, Dinh H, Trueblood ES, Pretorius I, Kugler D, Weng N, et al. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. *J Exp Med* (2007) 204(10):2367–51. doi:10.1084/jem.20070590

186. Mattioli B, Mattioli B, Pastorelli L, De Salvo C, Corradi D, Garg RR, et al. IL-33-dependent induction of intestinal profibrogenic and myofibroblast hypertrophy: potential role in inflammatory-associated gut fibrosis. *Gastroenterology* (2011) 140(5):S844–5.

187. De Salvo C, Wang X-M, Mattioli B, Pastorelli L, Garg RR, Chowdhry S, et al. Tu1950 pathogenic role of IL-33-mediated colon epithelial cell infiltration and function in experimental IBD. *Gastroenterology* (2012) 142(5):S885.

188. Sun P, Ben Q, Tu S, Dong W, Qi X, Wu Y. Serum interleukin-33 levels in patients with gastric cancer. *Dig Dis Sci* (2011) 56(2):3596–601. doi:10.1007/s10620-011-1760-5

189. De Vita F, Odrirura M, Galizia G, Romano C, Infusino S, Autiero A, et al. Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies. *Cancer* (1999) 86(10):1936–43. doi:10.1002/(SICI)1097-0142(19991115)86:10<1936::AID-CNCR9>3.0.CO;2-0

190. Johnstone A, Xing X, Guzman AM, Ribllet C, Loyd CM, Ward NL, et al. IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. *J Immunol* (2011) 186(4):2613–22. doi:10.4049/jimmunol.1003162

191. Muhr P, Zeitgeil J, Heriland I, Wierfel T, Wittmann M. Expression of interleukin (IL)-1 family members upon stimulation with IL-17 differs in keratinocytes derived from patients with psoriasis and healthy donors. *Br J Dermatol* (2011) 165(1):189–93. doi:10.1111/j.1365-2133.2011.09302.x

192. Carrier Y, Ma HL, Ramon HE, Naperiata L, Small C, O’Toole M, et al. Inter-regulation of Th17 cytokines and the IL-17 cytokines in vitro and in vivo: implications in psori- asis pathogenesis. *J Invest Dermatol* (2011) 131(12):2428–37. doi:10.1038/jid.2011.234

193. Ramadas RA, Li X, Shubitowski DM, Saminemis S, Wills-Karp M, Ewart SL. IL-1 Receptor antagonist as a positional candidate gene in a murine model of allergic asthma. *Immunogenetics* (2006) 58(10):851–5.

194. Ramadas RA, Ewart SL, Medoff BD, LeVine AM. Interleukin-1 family member 9 stimulates chemokine production and neutrophil influx in mouse lungs. *Am J Respir Cell Mol Biol* (2011) 44(2):134–45. doi:10.1165/rcmb.2009-0315OC

195. Ramadas RA, Ewart SL, Iwakura Y, Medoff BD, LeVine AM. IL-36alpha exerts pro-inflammatory effects in the lungs of mice. *Proc Natl Acad Sci U S A* (2012) 109(8):3001–5. doi:10.1073/pnas.1121534109

196. Costelloe C, Watson M, Murphy A, McQuillan K, Loscher C, Armstrong ME, et al. IL-1F5 mediates anti-inflammatory activity in the brain through induction of IL-4 following interaction with SIGIRR/TLR7. *J Neurochem* (2008) 105(5):1960–9. doi:10.1111/j.1471-4159.2008.05304.x

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any com- mercial or financial relationships that could be construed as a potential con- flict of interest.

Received: 06 April 2013; accepted: 24 June 2013; published online: 09 July 2013. Citation: Lopetuso LR, Chowdhry S and Pizzaro TT (2013) Opposing functions of classic and novel IL-1 family members in gut health and disease. *Front Immunol* 4:181. doi: 10.3389/fimmu.2013.00181 This article was submitted to Frontiers in Inflammation, a specialty of Frontiers in Immunology. Copyright © 2013 Lopetuso, Chowdhry and Pizzaro. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.